Ana de Carvalho Vaz1*, João Oliveira2, Diana Pinto3, Fernanda Teixeira3, Ana Rita Araújo3 and Laura Marques4
1Department of Pediatrics, Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal
2Department of Pediatrics, Centro Materno Infantil do Norte, Centro Hospitalar Universitário do Porto, Porto, Portugal
3Department of Pediatrics, Infectious Diseases and Immunodeficiencies Unit, Centro Materno Infantil do Norte, Centro Hospitalar Universitário do Porto, Porto, Portugal
4Department of Pediatrics, Infectious Diseases and Immunodeficiencies Unit, Centro Materno Infantil do Norte, Centro Hospitalar Universitário do Porto, Porto, Portugal
*Corresponding Author:Ana de Carvalho Vaz, Department of Pediatrics, Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal.
Received: March 15, 2022; Published: March 25, 2022
Poorly controlled moderate-to-severe atopic dermatitis in children and adolescents can result in growth failure, impaired quality of life of patients and their families and a significant increase in healthcare expenses. A 9-year-old boy with severe atopic dermatitis, who was initiated on off-label treatment with dupilumab and presented a significant improvement in dermatitis and quality of life. This case highlights the great potential of dupilumab in the treatment of severe atopic dermatitis in the pediatric population.
Keywords: Dupilumab; Atopic dermatitis; Quality of life; Eczema; Children
Citation: Ana de Carvalho Vaz., et al. “Dupilumab Successful Treatment of a Child with Severe Atopic Dermatitis”. Acta Scientific Paediatrics 5.4 (2022): 19-23.
Copyright: © 2022 Ana de Carvalho Vaz., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.